These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sublingual immunotherapy: dosing in relation to clinical and immunological efficacy. Larenas-Linnemann DE Allergy Asthma Proc; 2008; 29(2):130-9. PubMed ID: 18430309 [TBL] [Abstract][Full Text] [Related]
6. Advantages and disadvantages of accelerated immunotherapy schedules. Cox L J Allergy Clin Immunol; 2008 Aug; 122(2):432-4. PubMed ID: 18619664 [No Abstract] [Full Text] [Related]
7. Immunotherapy with allergens. Creticos PS; Norman PS JAMA; 1987 Nov; 258(20):2874-80. PubMed ID: 3312669 [No Abstract] [Full Text] [Related]
8. Historical perspectives of allergy and immunology and allergen immunotherapy. Lockey RF Ann Allergy Asthma Immunol; 2014 Dec; 113(6):587-92. PubMed ID: 25454016 [No Abstract] [Full Text] [Related]
9. [GUIDE TO ALLERGEN IMMUNOTHERAPY FOR MITE ALLERGY]. Gotoh M Arerugi; 2017; 66(6):788-791. PubMed ID: 28701643 [No Abstract] [Full Text] [Related]
10. Clinical practice guidelines and specific antigen immunotherapy. Fornadley JA Otolaryngol Clin North Am; 2003 Oct; 36(5):789-802, v. PubMed ID: 14743773 [TBL] [Abstract][Full Text] [Related]
11. Monitoring the effect of allergen immunotherapy: a clinician's dream comes true? Bullens DM Clin Exp Allergy; 2010 Jul; 40(7):958-61. PubMed ID: 20642573 [No Abstract] [Full Text] [Related]
12. Adjuvants and vector systems for allergy vaccines. Moingeon P; Lombardi V; Saint-Lu N; Tourdot S; Bodo V; Mascarell L Immunol Allergy Clin North Am; 2011 May; 31(2):407-19, xii. PubMed ID: 21530828 [TBL] [Abstract][Full Text] [Related]
13. Specific immunotherapy by different allergen applications: subcutaneous, sublingual, oral or rectal administration and lymph node injection. Kleine-Tebbe J Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():87-95; discussion 95. PubMed ID: 20799448 [No Abstract] [Full Text] [Related]
14. Allergen immunotherapy (AIT) for the multiple-pollen sensitive patient. Nelson HS Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1443-1451. PubMed ID: 27687128 [TBL] [Abstract][Full Text] [Related]
15. [Specific immunotherapy in allergies--evaluation of current status]. Jarisch R; Hemmer W Wien Med Wochenschr; 1996; 146(15):422-5. PubMed ID: 9012204 [TBL] [Abstract][Full Text] [Related]
16. [Status report on allergen immunotherapy (hyposensitisation). Prepared by the WHO/IUIS Immunotherapy Subcommittee 1988]. Malling HJ Ugeskr Laeger; 1989 Nov; 151(48):3249-52. PubMed ID: 2595857 [No Abstract] [Full Text] [Related]
17. Risk factors for systemic reactions to allergen-specific subcutaneous immunotherapy. Iglesias-Cadarso A; Hernández-Weigand P; Reaño M; Pérez-Pimiento A; Vargas Núñez JA; de la Torre F J Investig Allergol Clin Immunol; 2010; 20(7):621-2. PubMed ID: 21314007 [No Abstract] [Full Text] [Related]
18. Rush injection therapy for asthma and allergic rhinitis. Greenberger PA Ann Allergy; 1994 Nov; 73(5):378-80. PubMed ID: 7978528 [No Abstract] [Full Text] [Related]
19. Treatment of respiratory allergy with allergy immunotherapy tablets. Bachert C Allergy; 2011 Jul; 66 Suppl 95():57-9. PubMed ID: 21668858 [TBL] [Abstract][Full Text] [Related]